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Abstract
Nearly 3.3 billion people globally are at risk of malaria, with 1.2 billion being at high
risk. Children under 5 years of age and pregnant women in sub-Saharan Africa still
account for a higher percentage of malaria-related mortalities, despite recent reports of
decline  in  malaria  mortalities  in  Africa.  Majority  of  these  deaths  are  caused  by
Plasmodium falciparum,  a  lethal  malaria  parasite  which has developed resistance to
different classes of antimalarial drugs and is responsible for complicated, severe disease.
To  forestall  the  debilitating  impact  of  the  disease  and  provide  safe  and  effective
alternative therapies, medicinal plants have been explored as a source of new antima-
larials. The isolation of quinine and artemisinin from plants present medicinal plants as
a  robust  source  of  effective  antimalarials.  In  this  chapter,  we review the  different
approaches employed in antimalarial discovery from plants, different classes of plant
antimalarial compounds and their proposed mechanisms of action. Compounds that
show potential for further development based on their high efficacy and selectivity are
also highlighted. Common obstacles encountered in the process of antimalarial drug
discovery from plant sources are identified and prospects for the identification of new,
effective antimalarial components from plant sources are also discussed.
Keywords: Antiplasmodial screening, Antimalarial, Medicinal plants, Plasmodium fal‐
ciparum, Selectivity
1. Introduction
Malaria has remained a leading cause of mortality in close to 100 countries where nearly
2.4  billion  people  reside,  almost  half  of  whom are  located  in  sub-Saharan  Africa.  With
continuous malaria transmission all year round and increasing rates of human movement
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in disease-endemic areas, a high burden of antimalarial use in these areas has contributed
to  global  malaria  burden  [1].  Exposure  of  parasites  to  suboptimal  antimalarial  drug
concentrations favors the selection of parasites with traits that enable them to survive in the
presence of the drug [2]. Over time, the most lethal strain of the malaria parasite, Plasmodium
falciparum, has developed resistance to many classes of antimalarial drugs and this contrib-
utes to the development of severe malaria complications which can be fatal without prompt
treatment. Other less lethal strains, P. ovale and P. vivax, can exist as latent hypnozoites in
the liver which can initiate a relapse months to years after the initial  infection [3].  With
increased global warming, it has been predicted that the geographic area covered by the
malaria vector,  Anopheles  will  increase species and this  will  cause wider transmission of
malaria parasites that are resistant to most of the antimalarials presently available [4]. Thus,
it  has  become necessary  to  develop versatile,  robust  alternatives  to  current  antimalarial
regimens that would be effective against all malaria parasite strains. Within the last decade,
efforts have been made to identify new strategies to prevent and treat malaria [5]. Plants
have been identified as a robust source for antimalarial drug discovery and interestingly,
cinchona alkaloids (such as quinine and quinidine) and artemisinin obtained from plants
are still clinically relevant today for the treatment of severe malaria [6].
In order to fast-track the development of effective, alternative medicines from medicinal plants,
appropriate pre-clinical studies that confirm their safety and efficacy are required to provide
sound experimental data that establish an evidence base. The development of effective
medicines from plants is not without its challenges and efforts should be made to address these
especially with novel approaches to preclinical screening and clinical testing. Conventional
drug development is very time dependent and cost dependent but is rarely rewarding
eventually; as the number of approvals for new drugs has declined in recent years [7]. Hence,
we also explore the revisited “reverse pharmacology” paradigm to address this problem and
secure the future of antimalarial drug discovery.
1.1. Current status of drug discovery from plant sources
Many medicines used against different diseases including cancer, diabetes, hypertension,
neurodegenerative disorders and infectious diseases have been sourced from a plant or
designed based on scaffolds of compounds isolated from plants. The latest of these include
artemether (antimalarial), galantamine (for Alzheimer’s disease), nitisinone (for tyrosine-
associated metabolic disorder) and tiotropium (anticholinergic), which have all recently been
introduced in the United States or are currently involved in late-phase clinical trials [8]. Drug
discovery from medicinal plants involves a multi-thronged approach that includes, but is not
limited to traditional medicine practitioners, botanists, medicinal chemists, pharmacologists
and molecular biologists. Conventionally, plants are selected either randomly or based on their
claimed historical medicinal relevance and subjected to sequential extraction and purification
steps. This can be very tedious and time-consuming and more effective methods for identifying
new lead molecules from plants have been explored. These include chemoinformatics and
bioinformatics as tools for in silico drug discovery [9], systems/polypharmacology approach
which integrates oral bioavailability tests, druggability, blood-brain barrier permeation, target
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identification and network analysis owing to the complex composition of medicinal plant
extracts and their diverse physiological effects [10]. High throughput pharmacological screens
and genetic manipulation have also been applied to discover new drug leads from plants, in
which plants extracts are screened against an array of receptors with or without gene manip-
ulation and compared to existing drugs [11].
2. Approaches in antimalarial drug discovery
Six major approaches to antimalarial drug discovery have been identified and reviewed,
including the investigation of natural products [12]. A plant-based approach is particularly
useful in resource-poor, malaria-endemic areas where nearly one-fifth of patients rely on
herbal remedies to treat malaria and febrile illnesses [13]. The choice of plants for antimalarial
drug discovery may be based on both random and empirical methods to explore biodiversity
or through studies guided by traditional use of the plant in the treatment of fever. The latter
ethnopharmacological approach has been recognized to give higher success rates for finding
active compounds, as over 50% of extracts from ethnomedicinal plants were active in vivo and/
or in vitro [14].
2.1. Ethnopharmacology-based plant selection and extraction
Herbal medicines have played a pivotal role in health and disease management for many
centuries. Different ancient civilizations, including Mesopotamian, Indian ayurveda, ancient
traditional Chinese medicine and Greek unani medicine, show documented evidence for the
use of herbs in the treatment of different ailments. In Africa, knowledge of traditional medicine
constitutes part of a wholistic system, passed through generations by oral communication and
indigenous practices [15]. The scientific exploitation of herbs used ethnomedicinally for pain
relief, wound healing and abolishing fevers has resulted in the identification of a wide range
of compounds that have been developed as new therapeutics [16].
The major role of ethnopharmacology is to discover new plant-derived compounds based on
the traditional use of medicinal plants. The knowledge on the use of plants for fevers and other
symptoms of malaria is used to guide the selection of plants to be subjected to antimalarial
screening and isolation of active constituents. This is a favored and conservative approach in
drug discovery as historical use of a plant as medicine increases the possibility that safe and
pharmacologically active compounds would be isolated from it.
2.2. Preclinical efficacy studies
2.2.1. In vitro assays
In vitro cultures of asexual forms of P. falciparum are generally maintained in leukocyte-free
erythrocytes at 2–5% hematocrit, in Roswell Park Memorial Institute (RPMI) culture medium
supplemented with 5–10% human serum at 37°C under reduced oxygen conditions [17].
Advantages associated with this assay are the small amount of test sample required and its
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flexibility, as it has been adapted for high — throughput screening of large compound libraries.
With latest developments in image processing and automation technology, screening against
live parasites in host cells can also be run in 1536-well formats. Also, concentrations producing
50% inhibition (IC50) and 90% inhibition (IC90) can easily be obtained from drug-response
curves by nonlinear regression. Drawbacks to these assays include the need for continuous
parasite culture and more importantly, the exclusion of host in vivo factors which affect drug
disposition and action.
Detection of parasite growth in in vitro assays generally involves the examination of Giem-
sa-stained smears for viable parasites. This method is very time-consuming, lacks precision
and limits rapid, large-scale screening of compounds. Colorimetric determination of parasite
lactate dehydrogenase in the presence of nitro blue tetrazolium which is reduced to a for-
mazan derivative has been developed and used successfully [18]. Other methods have been
developed which rely on incorporation of radiolabeled metabolic precursors, measurement
of dye-stained parasite DNA by fluorimetry or flow cytometry and use of luminometry for
genetically modified parasites that express luciferase [19–21]. Fluorescence-based assays that
employ DNA-binding fluorophores have also been described, for example, the fluorimetric
method described by Benoît et al. [20] in which parasite growth is quantified by stained
DNA of viable parasites. Enzyme-linked immunosorbent assays (ELISAs) with monoclonal
antibodies which measure P. falciparum–specific antigen histidine-rich protein 2 (HRP2) or
Plasmodium  lactate dehydrogenase (pLDH) protein as index of parasite growth have also
been reported [22].
Culture conditions for other human and nonhuman Plasmodium species are reviewed in detail
elsewhere [23]. The culturing of exoerythrocytic sporozoites was elucidated by infecting a
primary culture of human hepatocytes with P. falciparum and P. vivax sporozoites [24]. Though
promising, this assay is rarely used as production of large number of sporozoites in insects is
a rate-limiting step. Only few in vitro assays have been developed for hypnozoites of P. vivax
and P. ovale and the monkey malaria parasite P. cynomolgi [25].
2.2.2. In vivo assays
Mouse models of malaria infection using rodent parasites are especially useful for studying
the pathological  effects  of  interactions between the host  and the parasite.  These models
predict clinical outcomes of infections such as parasitemia, sequestration of parasitized red
blood cells, splenomegaly, pulmonary edema and hematological and biochemical phenom-
ena. Laboratory rodent parasites such as P. berghei and P. yoelii are used for evaluation of
plant  extracts  and compounds  [26].  With  advances  in  genetic  manipulation,  humanized
mouse models to study blood- and liver-stage P. falciparum infections in genetically modified
mice have been recently reported [27]. These models have also been used in studying cell-
mediated immune responses to liver-stage malaria vaccines [28]. Preliminary tests against
P. vivax in non-human primate models like Aotus and Saimiri monkeys have also been car-
ried out [29].
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2.2.3. Bioactivity‐guided studies, compound isolation and identification
In common practice, traditional herbal remedies are prepared in water, either at room
temperature or by boiling to obtain a decoction. Alcoholic solvents are also used as they
produce higher extract yield and extract a wider variety of chemical components compared to
aqueous extraction [30]. Separation and purification processes for antimalarial plant extracts
and fractions involve different chromatographic methods. Frequently, as the extract is
separated sequentially, antiplasmodial activity is monitored with a high-throughput in vitro
bioassay until the compounds responsible for activity are isolated. This method is based on
the assumption that antiplasmodial activity is limited to one or few compounds, whereas when
such activity is due to different compounds acting synergistically, it may be lost with further
separation [31]. Chromatographic procedures commonly employed include flash column,
medium- and high-pressure liquid chromatography and centrifugal countercurrent chroma-
tography. The structure of isolated compounds is determined on the basis of their spectroscopic
properties using mass spectrometry, ultraviolet and infrared spectroscopy and complete
proton and carbon mapping using one- and two-dimensional nuclear magnetic resonance
techniques. It has also been possible to use tandem or hyphenated techniques of these
spectroscopies for full stereochemical elucidation of constituents without isolation from
extracts [32]. The compound obtained is thereafter subjected to further testing, extending to
transmission and radical cure assays. Following the selection of a lead compound, it may be
optimized by synthesizing chemical derivatives with the desired bioavailability, potency and
selectivity before pre-clinical testing for efficacy and safety, preparatory for phase I clinical
testing [33].
3. Isolated compounds and antiplasmodial activity
Some examples of identified compounds that exhibit good antimalarial activity in vitro are
shown in Table 1. Criteria adopted for selection of the compounds shown were inhibition of
P. falciparum growth by 50% at a concentration of either < 5 μg/mL or < 5 μM in vitro, with high




ICSelectivity S = (1)
where EC50 = effective concentration required to inhibit cellular growth by 50% and IC50 =
concentration required to inhibit parasite growth by 50%.
From the compounds shown in Table 1, it is evident that a remarkable diversity of plant-
derived compounds exists and they can form good templates for the design of novel antima-
larials. One example of such is gedunin, a limonoid extracted from the leaves of Azadirachta
indica with high antiplasmodial activity in vitro. Its antiplasmodial potency was attributed to
the α,β-unsaturated ketone group in Ring A of its limonoid backbone, a 7α-acetate group as
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well as its furan ring [34]. Dichroa febrifuga is a popular fever remedy in traditional Chinese
medicine and guided studies led to the isolation and identification of febrifugine over 50 years
ago [35]. Studies on febrifugine were hindered for a long time because of its toxicity. Some of
its derivatives with good antiplasmodial activity have however been shown to exhibit lower
toxicity compared with the parent compound [35]. The monoterpene indole alkaloid ellipticine
and its isomer olivacine isolated from the bark of Aspidosperma olivaceum were shown to possess
antiplasmodial effects in addition to its previously reported antitumor properties [36]. The
selectivity of the ellipticine and olivacine for the parasitic targets was evident from the high S
values (500–1200, ellipticine and 330–390, olivacine) against P. falciparum K1 and 3D7 [36].
Ellipticine was shown to be antiplasmodial, by inhibiting heme crystal growth and interacting
with parasite DNA. It was speculated that this effect was similar to that of other analogous
cryptolepine- and harmane-type indole alkaloids, depending on structural similarity [36].
Uvaria leptocladon is a shrub growing in the West Usambara Mountains of Tanzania, where it
is used against cerebral malaria [37]. Investigation of the Tanzanian U. leptocladon root bark
afforded the isolation of the chalcones, uvaretin and diuvaretin, which were shown to possess
antiplasmodial activity with IC50 < 5 μg/mL [38]. Antiplasmodial screening of Dorstenia barteri
twigs yielded the isolation of the prenylated chalcones, bartericin A (IC50 = 2.15 μM) and 4-
hydroxylonchocarpin (IC50 = 3.36 μM) which were devoid of toxicity to erythrocytes at
concentrations below 20 mM [39]. The authors deduced that the presence of a hydroxylated
prenyl group on carbon 5′ on Ring B of bartericin A enhanced its antiplasmodial activity
compared to a prenyl group at the same position in 4-hydroxylonchocarpin [39]. Lanaroflavone
is a biflavonoid isolated from the methanol extract of the aerial part of Campnosperma panamense
Standl. In vitro screening revealed its highly selective (S = 159) antiplasmodial activity (IC50 =
0.48 μM) [40]. For this compound, it was observed that its C-4‴─O─C-8 interflavonoid linkage
was relevant for antiplasmodial activity [40].
A study of species of Carpesium genus used as traditional remedies for the treatment of parasite
infections led to the identification and isolation of ineupatorolide A, a sesquiterpene from
Carpesium rosulatum. Of particular interest were its high antiplasmodial activity (IC50 = 0.019
μM) and selectivity (S > 1000) [41]. Bowdichia nitida Spruce ex Benth., commonly referred to as
“sucupira,” is distributed in the Brazilian Amazon and the seeds of this plant are traditionally
used for rheumatic arthritis, fever and gouty arthritis [42]. 6α,7β-Diacetoxyvouacapane
isolated from a methanol extract of B. nitida seeds displayed high activity against P. falciparum
3D7 (IC50 0.39 μg/mL) and high selectivity for the parasite, as cytotoxic IC50 on COLO 201 cells
was higher than 100 μg/mL [42]. Another antiplasmodial compound identified as neosergeo-
lide, a quassinoid obtained from the root and stem of Picralemma sprucei, had high antiplas-
modial activity (0.002 μM) and was cytotoxic toward selected tumor cell lines at concentrations
ranging from 5 to 27 mg/mL [43]. Antiplasmodial activity-aided fractionation of Piptadenia
pervillei leaves afforded the identification of (+)-catechin-3-gallate and (+)-catechin-5-gallate,
which displayed high antiplasmodial effects against P. falciparum FcB1 and had no significant
cytotoxic effects against the human embryonic lung cells MRC-5 [44].
Other compounds have also been investigated and found highly active against hepatic stage
Plasmodium species. N-Cyclopentyl-tazopsine, a semisynthetic derivative of a plant-derived
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morphinan compound, tazopsine, was shown to have specific activity against liver-stage
parasites of P. falciparum (IC50 = 42.4 μM, S = 60) and P. yoelii (IC50 = 3.3 μM, S = 46) [45]. Its
efficacy against hepatic-stage parasites indicates its potential for development as a prophy-
lactic agent.
Compounds Plant source Family Antiplasmodial activity Source
Gedunin Azadirachta indica Meliaceae (Pf D6) 0.039 μg/mL
(Pf W2) 0.02 μg/mL
[34]
Febrifugine Dichroa febrifuga Hydrangeaceae (Pf W2) 0.53 ng/mL
(Pf D6) 0.34 ng/mL
[35]
Ellipticine Aspidosperma vargasii Apocynaceae (Pf K1) 0.81 μM
(Pf 3D7) 0.35 μM
[36]
Olivacine Aspidosperma olivaceum Apocynaceae (Pf K1) 1.4 μM
(Pf 3D7) 1.2 μM
[36]
Uvaretin Uvaria spp. Annonaceae (Pf K1) 3.49 μg/mL [37, 38]
Diuvaretin 4.20 μg/mL
Bartericin A Dorstenia barteri Moraceae (Pf W2) 2.15 μM [39]
4-Hydroxylonchocarpin 3.36 μM
Lanaroflavone Campnosperma panamense Anacardiaceae (Pf K1) 0.48 μM [40]
Ineupatorolide A Carpesium rosulatum Asteraceae (Pf D10) 0.019 μM [41]
6α,7β-Diacetoxyvouacapane Bowdichia nitida Leguminosae (Pf 3D7) 0.97 μM [42]
Neosergeolide Picralima sprucei Simaroubaceae (Pf K1) 0.002 μM [43]
(+)-Catechin-3-gallate Piptadenia pervillei Fabaceae (Pf FcB1) 1 μM [44]
(+)-Catechin-5-gallate 1.2 μM
Table 1. Antiplasmodial compounds with high selectivity isolated from plants.
4. Isolated compound classes and intra-parasitic targets
4.1. Alkaloids
This group of plant secondary metabolites represents the largest group of plant secondary
metabolites with the highest number of compounds displaying potent antiplasmodial activity.
They also serve as good templates for synthesis of many quinolone-based antimalarial drugs.
Alkaloids displaying potent antiplasmodial activity occur as steroidal alkaloids, bisbenzyli-
soquinolines, naphthylisoquinolines, indoloquinolines and indolomonoterpenoid alkaloids,
among others. Quinoline alkaloids isolated from the bark of Cinchona officinalis including
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quinine, quinidine, cinchonine and cinchonidine (Figure 1) are all highly effective against
malaria, with cure rates exceeding 98% in humans [33]. Although quinine is associated with
serious side effects, it has remained an important drug to treat severe malaria due to chloro-
quine resistance. Quinine is schizonticidal against all intraerythrocytic malaria parasites and
gametocytocidal for P. vivax and P. malariae, but not against P. falciparum gametocytes [46].
Figure 1. Chemical structures of cinchona alkaloids: quinine, quinidine, cinchonine and cinchonidine.
Although the mechanism of action of quinine has not been fully resolved, it has been reported
to exhibit inhibitory effects on heme polymerization and heme catalase activity [47]. Following
the success of quinine identification and use, natural antiplasmodial alkaloids have been
isolated and reviewed by Kaur et al. [48]. Some alkaloids have been reported to inhibit fatty
acid biosynthesis in the parasite [22], while some act as resistance reversers. The monoindole
alkaloids strychnobrasiline and malagashanine isolated from Strychnos myrtoides potentiated
the effects of chloroquine, quinolones, aminoacridines and halofantrine [49]. Malagashanine
has no intrinsic antiplasmodial or cytotoxic action, but aids chloroquine accumulation in drug-
resistant parasites by improving chloroquine influx and preventing its efflux from the
parasites [50].
4.2. Flavonoids and chalcones
Flavonoids occur ubiquitously in many higher plants where they act as growth regulators and
offer protection against plant pathogens [51]. They have been proposed to act by inhibiting the
fatty acid biosynthesis (FAS II) pathway, which is present in the parasite’s apicoplast but absent
in human hosts [52]. The flavonoid, luteolin-7-O-β-d-glucopyranoside, was reported as the
first natural product that targets plasmodial FAB I enzyme which regulates the FAS II path-
way [53]. Some flavonoids have also been shown to inhibit l-glutamine and myoinositol influx
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into infected erythrocytes or act by interfering with hemin degradation [54, 55]. In addition,
chalcones have been proposed to act by inhibiting cyclin-dependent protein kinases and
plasmepsin II [56].
4.3. Terpenes and terpenoids
In recent times, attention has been devoted to this class of compounds especially sesquiterpe-
noids, following the discovery of the endoperoxide sesquiterpene lactone; artemisinin. These
compounds are attractive because some possess intrinsic antiplasmodial activity and offer
good starting points for chemical modification into derivatives with desired physicochemical
properties and enhanced efficacy. Artemisinin and its derivatives owe their antiplasmodial
effects to the presence of an endoperoxide bridge that generates toxic-free radicals when it is
broken down (Figure 2). Another example of a highly potent antiplasmodial sesquiterpene is
ineupatorolide A (Table 1).
Apart from the major classes of isolated compounds discussed above, other examples such as
xanthones, stilbenes, coumarins, lignans, tannins and steroids have also been reported to
exhibit potent antiplasmodial effects [57].
Figure 2. Artemisinin and its chemical derivatives in clinical use.




Literature search revealed only few plant-derived extracts or compounds undergoing clinical
studies and these are shown in Table 2. Spirotetrahydro β-carbolines (spiroindolones) present
a unique group of compounds that share structural similarities with strictosamide, an iridoid
indole alkaloid identified in an extract of Nauclea pobeguinii stem bark, but also present in
Nauclea latifolia and Nauclea officinalis extracts [58, 59]. A spiroindolone (NITD609, Figure 3)
displayed low IC50 within the range of 0.5–1.4 nM, showed no evidence of diminished potency
against drug-resistant strains and was not significantly cytotoxic to mammalian cells [60, 61].
It was also effective against clinical isolates of P. falciparum and P. vivax (IC50 < 10nM) and
comparable to artesunate. Additionally, it inhibited gametocyte development in vitro and
oocyst development in mosquitoes [60]. Argemone mexicana decoction administered orally also
produced antimalarial effects that were comparable to artesunate-amodiaquine combination
in patients [62].
Plant extract/compound Stage of clinical development Mechanism of action
Nauclea pobeguinii [58] Phase IIb/III Not known
Argemone mexicana [62] Phase IIb/III Not known
NITD609 [60, 61] Phase IIa Chemotherapeutic, transmission blocking
Table 2. Plant extracts and natural product–derived compound in clinical development.
Figure 3. Chemical structures of strictosamine, an iridoid indole alkaloid and structurally similar spiroindolone in clin-
ical development, NITD609.
6. Reverse pharmacology: from bedside to bench
Conventional drug discovery and development is an energy-, time- and resource-demanding
venture; hence, the entire process results in minimal success rates. Millions of compounds are
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involved during initial screening and identified hits are ranked based on potency, ease of
synthesis, known limitations to therapeutic use and novelty to determine a possible lead
compound [33]. The lead compound is thereafter subjected to preclinical tests and various
optimization processes to confer desired chemical and pharmacokinetic properties on it before
final clinical testing. After passing through rigorous Phases I-III trials, it may be accorded
statutory approval for clinical use. This is very expensive and time-consuming and many
pharmaceutical companies are looking for new approaches in drug discovery that will lead to
expedited launch of new, effective and safe drugs.
Reverse pharmacology is a science that integrates well-documented clinical experiences and
observations toward lead development, through interdisciplinary studies (preclinical, clinical)
for drug development [63]. Here, “safety“ is the starting point as well-documented evidence
of traditional use as medicine. This provides an important basis for further scientific testing.
Hence, reverse pharmacology adopts a “bedside to bench” approach, compared to conven-
tional “bench to bedside” drug discovery and development.
The use of Artemisia annua as treatment for fever and malaria in traditional Chinese medicine
afforded the discovery of artemisinin through a reverse pharmacology approach. Today,
artemisinin derivatives like artemether, artesunate, artemether and dihydroartemisinin
remain useful antimalarial agents against drug-sensitive and drug-resistant malaria. However,
the case of artemisinin is a unique one where artemisinin was identified as an active molecule,
as not all traditional medicinal herbal extracts owe their therapeutic effects to a single chemical
entity. The effects of some extracts may be due to different phytochemicals acting on different
targets or a synergistic effect between different constituents and further separation and
purification may lead to a loss of activity [30]. In this case, bioactivity markers should be
identified and a standardized formulation of the extract should be prepared and screened
using a systems biology approach before consideration for further development.
An example of antimalarial drug development using the reverse pharmacology approach in
recent times is seen in the study of a standardized extract of A. mexicana for the treatment of
malaria [64]. Initially, the authors conducted a retrospective treatment-outcome study to select
a candidate for development before a dose-escalating clinical study to identify and choose a
dose with desirable safety and efficacy. Next, they carried out a randomized controlled trial
for comparison of the selected phytomedicine with conventional first line antimalarial therapy
followed by identification of active compounds which could be employed as chemical markers
to standardize the phytomedicine. This scheme was used successfully and can be adopted for
antimalarial drug development (Figure 4). The process of identifying chemical and/or
biological markers of efficacy which are used to ensure herbal medicine quality is known as
standardization. This is an important step in drug development from herbal medicines, as
quantity and quality of secondary metabolites depend on intrinsic factors, environmental
factors and biotic factors [65].
It is interesting to note that subsequent to the report on the clinical efficacy of A. mexicana [62],
three antiplasmodial protoberine-type alkaloids were isolated by conventional methods from
an extract of A. mexicana, namely, berberine, allocryptopine and protopine, but berberine was
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found to be cytotoxic relative to the parent extract, while allocryptopine and protopine were
more selective for parasites compared to berberine [66] (see Figure 4).
Figure 4. Antimalarial drug development by reverse pharmacology flow chart as described by Willcox et al. [64],
showing key personnel involved during each stage of the process.
7. Conclusions
Naturally occurring antiplasmodial compounds in plants show vast chemical diversity but
also exist within a complex mixture of other plant secondary metabolites which in itself
constitutes a major challenge to efforts in identifying compounds responsible for biological
effects. Other problems with plant-based drug discovery process range from the basic ones
like sustainable access to plant material, seasonal and environmental variations and legislative
issues concerning plant use, to challenges concerning complex fractionation procedures, small
quantity of pure compounds and poor pharmacokinetic/physicochemical properties that
negatively affect druggability [67]. With an increasing understanding and use of genomics, it
is possible that bioactive molecules can be produced more efficiently using plant-cell cultures
and genetically modified microbes [68]. This has already been exploited in the production of
artemisinin precursors from genetically modified Saccharomyces cerevisiae and Escherichia coli
[69].
Innovative drug discovery through reverse pharmacology or conventional methods especially
in resource-constrained remote areas where medicines are urgently needed should be given
more attention. There is the need to explore other aspects of the use of plant extracts and
compounds as efficacy boosters or drug resistance reversers in combination with conventional
therapy [50]. Efficacy screening against the parasite at all stages of development including
gametocytes and hypnozoites should be incorporated in preclinical drug testing as they are
often overlooked yet useful tools to identify agents that block transmission of resistance and
prevent relapse [70]. In the course of literature review, a number of antimalarial compounds
reported also displayed significant cytotoxic effects on human cells. Thus, screening for
inhibitors against parasite-specific targets in organelles like the apicoplast and pathways such
as heme degradation and type II fatty acid biosynthesis would likely identify active leads with
highly selective antiplasmodial action.
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